O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
(-7.6%)
Cap. Flow
+$275M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
1.6
years
Avg Time Held Equity only
1.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Neuropace
NPCE
|
+$93.1M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$77.8M |
| 4 |
Janux Therapeutics
JANX
|
+$77.2M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$74.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$94.6M |
| 2 |
AbCellera Biologics
ABCL
|
+$54.5M |
| 3 |
Adverum Biotechnologies
ADVM
|
+$54.2M |
| 4 |
Molina Healthcare
MOH
|
+$38M |
| 5 |
PAND
Pandion Therapeutics Inc. Common Stock
PAND
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.72% |
| 2 | Miscellaneous | 4.15% |
| 3 | Technology | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CTIC
101
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $18.8M | 0.19% |
7,520,600
| – | – |
2017 Q2
16 quarters
|
|
102
Verrica Pharmaceuticals
VRCA
$65.8M
| $16.7M | 0.17% |
147,973
| – | – |
2018 Q2
12 quarters
|
|
103
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $15.9M | 0.16% |
230,905
| – | – |
2021 Q1
1 quarter
|
|
104
Nautilus Biotechnolgy
NAUT
$275M
| $15.6M | 0.16% |
1,546,700
+1,497,325
| +3,033% | +$16.2M |
2021 Q1
1 quarter
|
|
105
Vor Biopharma
VOR
$1.11B
| $15.5M | 0.16% |
41,667
| – | – |
2021 Q1
1 quarter
|
|
|
ACHL
106
DELISTED
Achilles Therapeutics
ACHL
| $15.5M | 0.16% |
1,584,845
| – | – |
2021 Q1
1 quarter
|
|
|
JNCE
107
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $14.6M | 0.15% |
2,147,400
+323,800
| +18% | +$2.69M |
2021 Q1
1 quarter
|
|
108
uniQure
QURE
$1.45B
| $14.5M | 0.15% |
471,174
-497,905
| -51% | -$16.7M |
2019 Q2
8 quarters
|
|
109
DELISTED
Synlogic
SYBX
| $14.4M | 0.15% |
246,444
+111,111
| +82% | +$6.07M |
2017 Q3
15 quarters
|
|
110
Milestone Pharmaceuticals
MIST
$98.1M
| $14.2M | 0.14% |
2,583,821
| – | – |
2020 Q3
3 quarters
|
|
111
Amgen
AMGN
$230B
| $13.9M | 0.14% |
57,100
-34,400
| -38% | -$8.46M |
2013 Q2
32 quarters
|
|
112
Relay Therapeutics
RLAY
$3.74B
| $12.8M | 0.13% |
350,000
| – | – |
2020 Q3
3 quarters
|
|
113
Alector
ALEC
$210M
| $12.7M | 0.13% |
611,478
| – | – |
2019 Q1
9 quarters
|
|
|
HLSQ
114
Tessera Defense and Homeland Security Inc.
HLSQ
$2.15M
| $12.6M | 0.13% |
1,218
| – | – |
2019 Q4
6 quarters
|
|
115
DELISTED
WM TECHNOLOGY INC A
MAPS
| $12.5M | 0.13% |
700,400
| – | – |
2021 Q1
1 quarter
|
|
|
BLU
116
DELISTED
BELLUS Health Inc.
BLU
| $12.3M | 0.12% |
3,954,800
| – | – |
2019 Q3
7 quarters
|
|
117
Jade Biosciences
JBIO
$855M
| $12.2M | 0.12% |
+15,306
| New | +$12.2M |
2021 Q2
0 quarters
|
|
118
Insight Molecular Diagnostics
IMDX
$91.3M
| $12.1M | 0.12% |
105,000
| – | – |
2021 Q1
1 quarter
|
|
119
Century Therapeutics
IPSC
$250M
| $11.9M | 0.12% |
+407,047
| New | +$10.3M |
2021 Q2
0 quarters
|
|
|
CNVY
120
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $11.4M | 0.12% |
+1,000,000
| New | +$11.6M |
2021 Q2
0 quarters
|
|
121
CVRx
CVRX
$35.7M
| $11.2M | 0.11% |
+400,000
| New | +$11.2M |
2021 Q2
0 quarters
|
|
122
CALL
Boston Scientific
BSX
$62.3B
| $10.7M | 0.11% |
+250,000
| New | +$10.5M |
2021 Q2
0 quarters
|
|
123
PUT
DELISTED
CureVac
CVAC
| $10.3M | 0.1% |
+140,000
| New | +$14M |
2021 Q2
0 quarters
|
|
124
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $10M | 0.1% |
183,750
| – | – |
2020 Q4
2 quarters
|
|
125
CytomX Therapeutics
CTMX
$486M
| $9.58M | 0.1% |
+1,513,168
| New | +$11.8M |
2021 Q2
0 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2021 Portfolio in Review
As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.
- OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
- OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
- OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
- OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
- OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
- OrbiMed opened 24 new positions and closed 24 in Q2 2021.
- OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.
Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.